Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients

Johnson & Johnson (NYSE:JNJ) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension (OLE), evaluating the long-term efficacy and safety of nipocalimab in a broad population of antibody-positive adults with generalized myasthenia gravis (gMG).

Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL (activities of daily living) and QMG (quantifies disease severity) scores over 84 weeks with sustained reductions in total immunoglobulin G (IgG).

Nipocalimab demonstrated a mean change in MG-ADL of -5.64 (p<0.001) after 60 weeks in the OLE for study participants receiving nipocalimab and SOC, and -6.01 (p<0.001) mean change for study participants ...

https://www.benzinga.com/general/biotech/25/04/44698541/johnson-johnsons-new-compelling-data-shows-sustained-symptom-improvement-in-muscular-disease-pati